John A. Lewicki
2017
In 2017, John A. Lewicki earned a total compensation of $1.7M as President and Chief Executive Officer at OncoMed Pharmaceuticals, a 151% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $167,911 |
|---|---|
| Option Awards | $967,675 |
| Salary | $419,777 |
| Stock Awards | $192,925 |
| Total | $1,748,288 |
Lewicki received $967.7K in option awards, accounting for 55% of the total pay in 2017.
Lewicki also received $167.9K in non-equity incentive plan, $419.8K in salary and $192.9K in stock awards.
Rankings
In 2017, John A. Lewicki's compensation ranked 6,175th out of 14,666 executives tracked by ExecPay. In other words, Lewicki earned more than 57.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,175 out of 14,666 | 58th |
Division Manufacturing | 2,267 out of 5,768 | 61st |
Major group Chemicals And Allied Products | 718 out of 2,074 | 65th |
Industry group Drugs | 555 out of 1,730 | 68th |
Industry Pharmaceutical Preparations | 437 out of 1,329 | 67th |
Source: SEC filing on April 27, 2018.
Lewicki's colleagues
We found four more compensation records of executives who worked with John A. Lewicki at OncoMed Pharmaceuticals in 2017.